Titre : Régulation négative

Régulation négative : Questions médicales fréquentes

Termes MeSH sélectionnés :

Programmed Cell Death 1 Receptor
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Régulation négative : Questions médicales les plus fréquentes", "headline": "Régulation négative : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Régulation négative : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-07", "dateModified": "2025-05-02", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Régulation négative" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Phénomènes pharmacologiques", "url": "https://questionsmedicales.fr/mesh/D000069437", "about": { "@type": "MedicalCondition", "name": "Phénomènes pharmacologiques", "code": { "@type": "MedicalCode", "code": "D000069437", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G07.690.773" } } }, "about": { "@type": "MedicalCondition", "name": "Régulation négative", "alternateName": "Down-Regulation", "code": { "@type": "MedicalCode", "code": "D015536", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Mohammad Taheri", "url": "https://questionsmedicales.fr/author/Mohammad%20Taheri", "affiliation": { "@type": "Organization", "name": "Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran." } }, { "@type": "Person", "name": "Soudeh Ghafouri-Fard", "url": "https://questionsmedicales.fr/author/Soudeh%20Ghafouri-Fard", "affiliation": { "@type": "Organization", "name": "Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran." } }, { "@type": "Person", "name": "Susumu Ohya", "url": "https://questionsmedicales.fr/author/Susumu%20Ohya", "affiliation": { "@type": "Organization", "name": "Department of Pharmacology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan." } }, { "@type": "Person", "name": "Nelsy Beatriz Medina", "url": "https://questionsmedicales.fr/author/Nelsy%20Beatriz%20Medina", "affiliation": { "@type": "Organization", "name": "Instituto de Investigaciones Farmacológicas (ININFA). Facultad de Farmacia y Bioquímica. Universidad de Buenos Aires. CONICET. Buenos Aires, Argentina." } }, { "@type": "Person", "name": "María Clara Gravielle", "url": "https://questionsmedicales.fr/author/Mar%C3%ADa%20Clara%20Gravielle", "affiliation": { "@type": "Organization", "name": "Instituto de Investigaciones Farmacológicas (ININFA). Facultad de Farmacia y Bioquímica. Universidad de Buenos Aires. CONICET. Buenos Aires, Argentina. Electronic address: graviell@ffyb.uba.ar." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression.", "datePublished": "2024-03-20", "url": "https://questionsmedicales.fr/article/38505997", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/dom.15529" } }, { "@type": "ScholarlyArticle", "name": "Netrin-1 mitigates acute lung injury by preventing the activation of the Toll-like receptor 4/nuclear factor-κB (TLR4/NF-κB) signaling.", "datePublished": "2024-02-09", "url": "https://questionsmedicales.fr/article/38345562", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.18632/aging.205527" } }, { "@type": "ScholarlyArticle", "name": "Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.", "datePublished": "2024-02-06", "url": "https://questionsmedicales.fr/article/38390214", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fendo.2024.1330936" } }, { "@type": "ScholarlyArticle", "name": "Lupus-like membranous nephropathy during the postpartum period expressing glomerular antigens exostosin 1/exostosin 2 and phospholipase A2 receptor: a case report.", "datePublished": "2024-01-27", "url": "https://questionsmedicales.fr/article/38280123", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s13730-023-00848-w" } }, { "@type": "ScholarlyArticle", "name": "Aging changes the expression of adenosine receptors, insulin-like growth factor 1 (IGF1), and hypoxia-inducible factor 1α (HIF1α) in hypothalamic astrocyte cultures.", "datePublished": "2023-12-23", "url": "https://questionsmedicales.fr/article/38225985", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.nbas.2023.100104" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Phénomènes physiologiques", "item": "https://questionsmedicales.fr/mesh/D010829" }, { "@type": "ListItem", "position": 3, "name": "Phénomènes pharmacologiques et toxicologiques", "item": "https://questionsmedicales.fr/mesh/D002620" }, { "@type": "ListItem", "position": 4, "name": "Phénomènes pharmacologiques", "item": "https://questionsmedicales.fr/mesh/D000069437" }, { "@type": "ListItem", "position": 5, "name": "Régulation négative", "item": "https://questionsmedicales.fr/mesh/D015536" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Régulation négative - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Régulation négative", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-12", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Régulation négative", "description": "Comment diagnostiquer une régulation négative ?\nQuels tests sont utilisés pour évaluer la régulation négative ?\nQuels biomarqueurs indiquent une régulation négative ?\nLa régulation négative est-elle visible sur des imageries ?\nPeut-on mesurer la régulation négative in vivo ?", "url": "https://questionsmedicales.fr/mesh/D015536?mesh_terms=Programmed+Cell+Death+1+Receptor&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Régulation négative", "description": "Quels symptômes sont associés à la régulation négative ?\nLa régulation négative provoque-t-elle des douleurs ?\nY a-t-il des symptômes neurologiques ?\nLa régulation négative affecte-t-elle l'humeur ?\nDes symptômes métaboliques peuvent-ils apparaître ?", "url": "https://questionsmedicales.fr/mesh/D015536?mesh_terms=Programmed+Cell+Death+1+Receptor&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Régulation négative", "description": "Peut-on prévenir la régulation négative ?\nL'exercice physique joue-t-il un rôle ?\nLe stress impacte-t-il la régulation négative ?\nUne bonne hygiène de vie est-elle suffisante ?\nLes vaccinations influencent-elles la régulation ?", "url": "https://questionsmedicales.fr/mesh/D015536?mesh_terms=Programmed+Cell+Death+1+Receptor&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Régulation négative", "description": "Quels traitements ciblent la régulation négative ?\nLes inhibiteurs peuvent-ils aider ?\nY a-t-il des traitements naturels ?\nComment la nutrition influence-t-elle la régulation ?\nLes thérapies comportementales sont-elles efficaces ?", "url": "https://questionsmedicales.fr/mesh/D015536?mesh_terms=Programmed+Cell+Death+1+Receptor&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Régulation négative", "description": "Quelles complications peuvent survenir ?\nLa régulation négative peut-elle causer des cancers ?\nY a-t-il des risques cardiovasculaires ?\nDes troubles endocriniens peuvent-ils apparaître ?\nLa régulation négative affecte-t-elle la fertilité ?", "url": "https://questionsmedicales.fr/mesh/D015536?mesh_terms=Programmed+Cell+Death+1+Receptor&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Régulation négative", "description": "Quels sont les facteurs de risque principaux ?\nLe tabagisme est-il un facteur de risque ?\nL'alimentation influence-t-elle la régulation ?\nLe manque de sommeil est-il un risque ?\nLe vieillissement est-il un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D015536?mesh_terms=Programmed+Cell+Death+1+Receptor&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une régulation négative ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses d'expression génique peuvent être utilisés." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer la régulation négative ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests PCR et les microarrays sont couramment utilisés pour évaluer l'expression." } }, { "@type": "Question", "name": "Quels biomarqueurs indiquent une régulation négative ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux réduits de certaines protéines ou ARN peuvent indiquer une régulation négative." } }, { "@type": "Question", "name": "La régulation négative est-elle visible sur des imageries ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Non, elle nécessite des analyses moléculaires pour être détectée." } }, { "@type": "Question", "name": "Peut-on mesurer la régulation négative in vivo ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des techniques comme l'imagerie par résonance magnétique fonctionnelle peuvent aider." } }, { "@type": "Question", "name": "Quels symptômes sont associés à la régulation négative ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes varient selon le contexte, mais peuvent inclure fatigue ou dysfonctionnement cellulaire." } }, { "@type": "Question", "name": "La régulation négative provoque-t-elle des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Indirectement, si elle affecte des processus biologiques liés à la douleur." } }, { "@type": "Question", "name": "Y a-t-il des symptômes neurologiques ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles neurologiques peuvent survenir si des gènes régulés affectent le système nerveux." } }, { "@type": "Question", "name": "La régulation négative affecte-t-elle l'humeur ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut influencer l'humeur si elle impacte des neurotransmetteurs ou hormones." } }, { "@type": "Question", "name": "Des symptômes métaboliques peuvent-ils apparaître ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la régulation négative peut perturber le métabolisme, entraînant divers symptômes." } }, { "@type": "Question", "name": "Peut-on prévenir la régulation négative ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Prévenir les facteurs de risque et maintenir un mode de vie sain peut aider." } }, { "@type": "Question", "name": "L'exercice physique joue-t-il un rôle ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut influencer positivement l'expression génique." } }, { "@type": "Question", "name": "Le stress impacte-t-il la régulation négative ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut exacerber la régulation négative de certains gènes." } }, { "@type": "Question", "name": "Une bonne hygiène de vie est-elle suffisante ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut réduire les risques, mais d'autres facteurs génétiques et environnementaux jouent aussi." } }, { "@type": "Question", "name": "Les vaccinations influencent-elles la régulation ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Certaines vaccinations peuvent moduler l'expression immunitaire, mais pas directement la régulation négative." } }, { "@type": "Question", "name": "Quels traitements ciblent la régulation négative ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies géniques et des médicaments peuvent être utilisés pour moduler l'expression." } }, { "@type": "Question", "name": "Les inhibiteurs peuvent-ils aider ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les inhibiteurs de certaines voies de signalisation peuvent réduire la régulation négative." } }, { "@type": "Question", "name": "Y a-t-il des traitements naturels ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Certaines plantes médicinales peuvent influencer l'expression génique, mais des études sont nécessaires." } }, { "@type": "Question", "name": "Comment la nutrition influence-t-elle la régulation ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut moduler l'expression des gènes et réduire la régulation négative." } }, { "@type": "Question", "name": "Les thérapies comportementales sont-elles efficaces ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent aider à gérer les symptômes associés, mais ne ciblent pas directement la régulation." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des maladies chroniques ou des troubles métaboliques peuvent résulter d'une régulation négative prolongée." } }, { "@type": "Question", "name": "La régulation négative peut-elle causer des cancers ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une régulation négative de gènes suppresseurs de tumeurs peut augmenter le risque de cancer." } }, { "@type": "Question", "name": "Y a-t-il des risques cardiovasculaires ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des déséquilibres dans l'expression génique peuvent contribuer à des maladies cardiovasculaires." } }, { "@type": "Question", "name": "Des troubles endocriniens peuvent-ils apparaître ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la régulation négative peut affecter les hormones et entraîner des troubles endocriniens." } }, { "@type": "Question", "name": "La régulation négative affecte-t-elle la fertilité ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut perturber l'équilibre hormonal et affecter la fertilité chez les individus." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque principaux ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs génétiques, environnementaux et le mode de vie peuvent influencer la régulation négative." } }, { "@type": "Question", "name": "Le tabagisme est-il un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut induire une régulation négative de gènes liés à la santé pulmonaire." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle la régulation ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation déséquilibrée peut affecter l'expression génique et la régulation." } }, { "@type": "Question", "name": "Le manque de sommeil est-il un risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le manque de sommeil peut perturber la régulation des gènes liés au stress et à la santé." } }, { "@type": "Question", "name": "Le vieillissement est-il un facteur de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le vieillissement peut affecter la régulation négative des gènes, augmentant les risques de maladies." } } ] } ] }

Sources (10000 au total)

Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression.

The cardiovascular benefits provided by glucagon-like peptide-1 receptor agonists (GLP-1RAs) extend beyond weight reduction and glycaemic control. One possible mechanism may relate to blood pressure (... A comprehensive database search for placebo-controlled randomized controlled trials on GLP-1RA treatment was conducted until December 2023. Data extraction and quality assessment were carried out, emp... Compared with placebo, GLP-1RAs modestly reduced SBP [semaglutide: MD -3.40 (95% CI -4.22 to -2.59, p < .001); liraglutide: MD -2.61 (95% CI -3.48 to -1.74, p < .001); dulaglutide: MD -1.46 (95% CI -2... Patients on GLP-1RA experienced modest SBP lowering compared with placebo. This observed effect was associated with weight/body mass index reduction and better glycaemic control, which suggests that B...

Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used due to their profound efficacy in glycemic control and weight management. Within real-world contexts, the manifestation of certain... We retrieved reports of AEs associated with treatment with GLP-1 RAs during the period from the first quarter (Q1) of 2004 to Q1 2023 from the FDA Adverse Event Reporting System (FAERS) database. Desc... A total of 8,240 reports of psychiatric AEs were analyzed out of 181,238 AE reports with treatment with GLP-1 RAs. Among these cases, a higher percentage was represented by women compared to men (65.8... Our findings demonstrate a significant association between GLP-1 RAs and the development of specific psychiatric AEs. Despite the observational nature of this pharmacovigilance study and the inherent ...

Extracellular tau stimulates phagocytosis of living neurons by activated microglia via Toll-like 4 receptor-NLRP3 inflammasome-caspase-1 signalling axis.

In tauopathies, abnormal deposition of intracellular tau protein followed by gradual elevation of tau in cerebrospinal fluids and neuronal loss has been documented, however, the mechanism how actually...

Relationship Between Angiotensin II Type 1 Receptor Antibody Positivity and Cytokine Gene Polymorphism in Renal Transplant Patients When Organ Rejection Occurs.

Kidney transplant remains the gold standard for the treatment of end-stage renal disease. Relationships between the presence of non-HLA antibodies, antibodies to AT1R, and cytokine gene polymorphisms ... Our study included 100 pediatric and adult kidney transplant patients plus 50 healthy controls. Levels of AT1R antibodies (by enzyme-linked immunosorbent assay) and gene polymorphisms of the cytokines... We found no statistically significant relationship between levels of antibodies to AT1R and gene polymorphisms among the studied cytokines in patients with rejection compared with the healthy controls... Because we observed that some gene polymorphisms among the studied cytokines may affect AT1R antibody levels, future studies are needed to understand the mechanism of the relationship. In addition, st...

Hypoglycemia Risk With SGLT2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists Versus Sulfonylureas Among Medicare Insured Adults With CKD in the United States.

Information on safety issues of newer glucose-lowering medications from a large population perspective in chronic kidney disease (CKD) patients with type 2 diabetes is limited. Our study aimed to exam... Retrospective cohort.... The 20% random sample of Medicare fee-for-service claims, 2012-2018.... Use of SGLT2is, GLP-1RAs, or sulfonylureas.... Hypoglycemic events resulting in health care utilization.... Cox proportional hazard model evaluated the 90-day risk of hypoglycemia associated with SGLT2is or GLP-1RAs versus sulfonylureas.... A total of 18,567 adults (mean age: 73 years) with CKD and type 2 diabetes was included; 14.0% (... CKD and type 2 diabetes diagnosis, CKD stage, and patient clinical status were identified with diagnosis or procedure codes. There is potential for residual confounding with use of retrospective data.... Use of SGLT2is or GLP-1RAs compared with sulfonylureas was associated with a lower risk of hypoglycemia among patients with CKD and type 2 diabetes. Black race was not only associated with lower use o...